Open-label uridine for treatment of depressed adolescents with bipolar disorder
Douglas G Kondo, Young-Hoon Sung, Tracy L Hellem, Kristen K Delmastro, Eun-Kee Jeong, Namkug Kim, Xianfeng Shi, Perry F Renshaw, Douglas G Kondo, Young-Hoon Sung, Tracy L Hellem, Kristen K Delmastro, Eun-Kee Jeong, Namkug Kim, Xianfeng Shi, Perry F Renshaw
Abstract
This report is an open-label case series of seven depressed adolescents with bipolar disorder treated with uridine for 6 weeks. Treatment response was measured with the Children's Depression Rating Scale-Revised and the Clinical Global Impressions scale. Uridine was associated with decreased depressive symptoms, and was well tolerated by study participants. Further systematic studies of uridine are warranted.
Figures
CDRS-R scores during 6 weeks of treatment with uridine. CDRS-R = Children's Depression Rating Scale-Revised.
Source: PubMed